TY - JOUR
T1 - Gene expression assay in the management of early breast cancer
AU - Caputo, Roberta
AU - Cianniello, Daniela
AU - Giordano, Antonio
AU - Piezzo, Michela
AU - Riemma, Maria
AU - Trovò, Marco
AU - Berretta, Massimiliano
AU - De Laurentiis, Michelino
N1 - Funding Information:
AG is supported by the Hollings Cancer Center's K12 Paul Calebresi Clinical and Translational Oncology Training Program K12 CA157688.
Funding Information:
MDL has participated in Advisory Boards and Steering Committees for Roche, Novartis, Genomic Health, Astra-Zeneca, Pfizer; MDL has received research grants from Roche and Astra-Zeneca; MDL has received speaking honoraria from Roche, Novartis, Genomic Health, Astra-Zeneca, Pfizer.
Publisher Copyright:
© 2020 Bentham Science Publishers.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - The addition of adjuvant chemotherapy to hormonal therapy is often considered ques-tionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treat-ment-related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physi-cian’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adju-vant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).
AB - The addition of adjuvant chemotherapy to hormonal therapy is often considered ques-tionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treat-ment-related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physi-cian’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adju-vant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).
KW - Adjuvant chemotherapy
KW - Early breast cancer (EBC)
KW - Estrogen receptor positive (ER)
KW - MapQuant Dx
KW - Oncotype DX
UR - http://www.scopus.com/inward/record.url?scp=85086035454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086035454&partnerID=8YFLogxK
U2 - 10.2174/0929867326666191205163329
DO - 10.2174/0929867326666191205163329
M3 - Review article
VL - 27
SP - 2826
EP - 2839
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 17
ER -